Jun 2026 (Q2 FY26) — Aug 4, 2026
Syndax Q2 FY26 — Strong Commercial Growth and Pipeline Advancement
Read the full callSyndax (SNDX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Syndax earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 72.8 | +91.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -55.0 | +127.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -49.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$13.65 +0.89% · +$0.12
Performance −10.8% 1Y
1Y: $15.31 on 14 Oct 2025 → $13.65. High $25.15 (2 Apr 2026), low $13.11 (27 Oct 2025).
- Previous close
- $13.53
- 52-week range
- $13.11 – $25.15
- One year
- −9.24%
Overview
- Symbol
- SNDX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Syndax earnings calls (SNDX)
Financials
What the filings say
Net profit, year on year: +31% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 8 | 20 | 38 | 46 | — | 65 | 73 |
| Operating profit | -90 | -96 | -84 | -69 | -57 | -63 | -34 | -40 |
| Operating margin | −716.6% | −1254.8% | −417.9% | −182.7% | −125.2% | — | −52.7% | −55.0% |
| Other income | 5 | 2 | -1 | -2 | -3 | -5 | -8 | -9 |
| Interest | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -84 | -94 | -85 | -72 | -61 | -68 | -43 | -49 |
| EPS ($ per share) | -0.98 | — | -0.98 | -0.83 | -0.70 | — | -0.48 | -0.55 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -439 | -495 | -569 | -544 | -693 | -902 | -1,221 | -1,507 |
| Total liabilities | 31 | 32 | 48 | 41 | 30 | 59 | 437 | 465 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 47 | 35 | 178 | 218 | 401 | 275 | 419 | 259 |
| Total assets | 84 | 64 | 301 | 450 | 497 | 613 | 725 | 530 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -69 | -51 | -71 | 29 | -134 | -161 | -275 | -323 |
| Cash from investing | 51 | 13 | -143 | -41 | -186 | 118 | -220 | 290 |
| Cash from financing | 16 | 29 | 304 | 118 | 172 | 264 | 353 | 14 |
| Net cash flow | -1 | -9 | 91 | 107 | -148 | 221 | -141 | -19 |
| Capital expenditure | -0 | — | 0 | -0 | 0 | 0 | 0 | -0 |
| Free cash flow | -69 | — | -71 | 29 | -134 | -161 | -275 | -323 |
Insider filings
26 filings between Dec 1, 2025 and Jul 8, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.75M
9 sales by 3 insiders
33% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 12
- Award — granted as compensation
- 3
- Option exercise — converted options into shares
Also filed: 1 gift, 1 other.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Metzger Michael A | — | $1.43M | Jul 8, 2026 |
| Botwood Nicholas A.J. | — | $1.18M | Jun 12, 2026 |
| Goldan Keith A. | — | $137.0K | Jun 1, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 8, 2026 | Metzger Michael A Chief Executive Officer | Sale 10b5-1 plan | 32,375 | $784.8K |
| Jul 8, 2026 | Metzger Michael A Chief Executive Officer | Option exercise 10b5-1 plan | 32,375 | $206.6K |
| Jun 12, 2026 | Botwood Nicholas A.J. Head of R&D, CMO | Option exercise 10b5-1 plan | 31,235 | $431.7K |
| Jun 12, 2026 | Botwood Nicholas A.J. Head of R&D, CMO | Sale 10b5-1 plan | 31,235 | $566.6K |
| Jun 11, 2026 | Botwood Nicholas A.J. Head of R&D, CMO | Sale 10b5-1 plan | 34,280 | $617.0K |
| Jun 11, 2026 | Botwood Nicholas A.J. Head of R&D, CMO | Option exercise 10b5-1 plan | 22,515 | $311.2K |
| Jun 1, 2026 | Metzger Michael A Chief Executive Officer | Sale | 6,847 | $130.0K |
| Jun 1, 2026 | Goldan Keith A. Chief Financial Officer | Sale | 1,177 | $22.4K |
| Feb 9, 2026 | Metzger Michael A Chief Executive Officer | Sale | 17,159 | $360.8K |
| Feb 9, 2026 | Goldan Keith A. Chief Financial Officer | Sale | 3,410 | $71.7K |
| Feb 6, 2026 | Metzger Michael A Chief Executive Officer | Sale | 7,412 | $152.8K |
| Feb 6, 2026 | Goldan Keith A. Chief Financial Officer | Sale | 2,082 | $42.9K |
| Feb 4, 2026 | Botwood Nicholas A.J. Head of R&D, CMO | Award | 24,000 | $0 |
| Feb 4, 2026 | Podlesak Dennis Director | Award | 48,000 | $0 |
| Feb 4, 2026 | Legault Pierre Director | Award | 24,000 | $0 |
| Feb 4, 2026 | Katkin Keith Director | Award | 24,000 | $0 |
| Feb 4, 2026 | Rizo Aleksandra Director | Award | 24,000 | $0 |
| Feb 4, 2026 | Botwood Nicholas A.J. Head of R&D, CMO | Award | 36,000 | $0 |
| Feb 4, 2026 | Huber Martin H. Jr. Director | Award | 24,000 | $0 |
| Feb 4, 2026 | Jarrett Jennifer Director | Award | 24,000 | $0 |
| Feb 4, 2026 | Goldan Keith A. Chief Financial Officer | Award | 21,500 | $0 |
| Feb 4, 2026 | Goldan Keith A. Chief Financial Officer | Award | 30,750 | $0 |
| Feb 4, 2026 | Metzger Michael A Chief Executive Officer | Award | 73,000 | $0 |
| Feb 4, 2026 | Metzger Michael A Chief Executive Officer | Award | 144,600 | $0 |
| Jan 30, 2026 | Goldan Keith A. Chief Financial Officer | Other | 1,219 | $10.3K |
| Dec 1, 2025 | Goldan Keith A. Chief Financial Officer | Gift | 1,224 | $0 |
| Sep 8, 2025 | Metzger Michael A Chief Executive Officer | Option exercise 10b5-1 plan | 157,307 | $1.71M |
| Sep 8, 2025 | Metzger Michael A Chief Executive Officer | Sale 10b5-1 plan | 157,307 | $2.58M |
| Aug 18, 2025 | Podlesak Dennis Director | Option exercise 10b5-1 plan | 19,200 | $138.2K |
| Aug 18, 2025 | Podlesak Dennis Director | Sale 10b5-1 plan | 19,200 | $304.2K |
| Aug 15, 2025 | Podlesak Dennis Director | Option exercise 10b5-1 plan | 19,200 | $138.2K |
| Aug 15, 2025 | Podlesak Dennis Director | Sale 10b5-1 plan | 19,200 | $298.4K |
| Aug 14, 2025 | Podlesak Dennis Director | Option exercise 10b5-1 plan | 19,200 | $138.2K |
| Aug 14, 2025 | Podlesak Dennis Director | Sale 10b5-1 plan | 19,200 | $272.5K |
| Jul 31, 2025 | Goldan Keith A. Chief Financial Officer | Other | 1,226 | $10.3K |
| Jul 16, 2025 | Metzger Michael A Chief Executive Officer | Sale | 7,534 | $70.0K |
| Jul 16, 2025 | Goldan Keith A. Chief Financial Officer | Sale | 1,296 | $12.0K |
| Mar 14, 2025 | Metzger Michael A Chief Executive Officer | Option exercise | 6,074 | $43.7K |
| Mar 4, 2025 | Metzger Michael A Chief Executive Officer | Option exercise 10b5-1 plan | 7,814 | $56.3K |
| Mar 4, 2025 | Metzger Michael A Chief Executive Officer | Sale 10b5-1 plan | 7,814 | $117.6K |
| Feb 10, 2025 | Gallagher Neil President, Head of R&D | Sale | 4,618 | $71.6K |
| Feb 10, 2025 | Metzger Michael A Chief Executive Officer | Sale | 13,288 | $206.0K |
| Feb 10, 2025 | Goldan Keith A. Chief Financial Officer | Sale | 3,777 | $58.6K |
| Feb 5, 2025 | Goldan Keith A. Chief Financial Officer | Award | 23,400 | $0 |
| Feb 5, 2025 | Legault Pierre Director | Award | 25,000 | $0 |
| Feb 5, 2025 | Huber Martin H. Jr. Director | Award | 25,000 | $0 |
| Feb 5, 2025 | Jarrett Jennifer Director | Award | 25,000 | $0 |
| Feb 5, 2025 | Katkin Keith Director | Award | 25,000 | $0 |
| Feb 5, 2025 | Meury William Director | Award | 25,000 | $0 |
| Feb 5, 2025 | Rizo Aleksandra Director | Award | 25,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Syndax Pharmaceuticals Inc
Free account. Everything above stays public.
Write why you follow Syndax Pharmaceuticals Inc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading